Clinical data and real-world results support the long-term efficacy of Biogen’s medications for multiple sclerosis (MS), according to scientific presentations being released by the company. Specifically, ... Read more
Four disease-modifying therapies (DMTs) for multiple sclerosis — Avonex, Rebif, Betaferon, and Copaxone — are cost-effective and reduce disease progression in MS patients, especially those with relapsing-remitting disease, according ... Read more
Abreos Biosciences announced the U.S. launch of moNATor, a laboratory-developed test that can help physicians monitor the levels of Tysabri (natalizumab) in patients with multiple sclerosis (MS). Tysabri (approved ... Read more
An approved lymphoma treatment, rituximab was found to be effective and safe for relapsing-remitting multiple sclerosis (RRMS) patients whose active disease has failed to respond to immunosuppressive ... Read more
New research shows that long-term Tysabri treatment of relapsing multiple sclerosis improves physical and mental health and leads to greater satisfaction with therapy.
Patients with MS experience ... Read more
The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completed a review on the risk for progressive ... Read more
Pin It on Pinterest